The Project PI is the Technical Director of the OSUCCC Genomics Shared Resources (GSR) and a Research Assistant Professor in the Division of Hematology at the OSU College of Medicine. She set up and directed the Illumina sequencing operation for close to 9 years now. As the GSR serves both the clinical/translational research community and the basic science communities at OSU, the Project PI has gained extensive insights related to the impact of quality (e.g., species, integrity, presence of contaminants, preservation process, nucleic acids extraction protocols) and quantity (concentration and total amount) of input material on sequencing library characteristics, sequencing data quality and read distributions in the genome. This wealth of knowledge helps to open up another front of research interest (in addition to DNA methylation and cancer epigenetics) for the PI resulting in the list of technology-related publications highlighted in the Biosketch document as well as the technology manuscripts under preparation as described in Research Strategy #3 and Research Strategy #5. For the R50 Application, the Mentor PIs (Dr. Muthusamy and Dr. Byrd) both share the same vision that properly controlled and well-designed low cell number- and single-cell RNA-seq in rare precursor populations in CLL and AML will allow us to evaluate the leukemic stem cell potential in CLL and AML, examine mechanism of drug sensitivity and biology in these rare cell populations. If successful, this research direction will open up avenues for novel therapies, relapse prevention and ultimately cellular level personalized medicine. As little is known about these precursor populations, careful characterization of their bulk transcriptomic profile is a reasonable first step to take to form the foundation of subsequent transcriptomic profiles from individual single-cells. Briefly, the overall research design is as follows: 1) standardize and optimize volume of cell sorting buffers for 10-, 50- and 100 cells; 2) use two types of external control RNA spike-in to correct for diverse total RNA in rare precursor cells; 3) guided by data from #2 to adjust for cell numbers to allow data normalization for between group comparisons with cell types with diverse RNA amount; 4) move forward with single-cell RNA-seq analysis guided by the most robust approaches available at that time (e.g., Fluidigm C1 or 10X Genomics and their single-cell RNA-seq kit)
/Relevance There are many types of slow-growing precursor cells in CLL and AML patient bone marrow samples and some or many of these inactive cells may be crucial cancer stem cells that are responsible for conferring drug resistance leading to cancer recurrence. This project proposes to combine the technical expertise of the Project PI with senior Mentor PIs with established drug development track record to systemically characterize these quiescent cells without inducing technique-related biases that can stunt the differences between these cell types. Upon knowing their unique cellular activities, these researchers will study how gene activities are impacted by standard and novel therapeutics leading to drug evasion.
